Lpath, Inc. has temporarily suspended dosing of iSONEP in its PEDigree and Nexus trials. The FDA informed Lpath that its fill/finish contractor, Formatech, Inc., was not in compliance with cGMP requirements during the period that the iSONEP clinical vials were filled. Lpath has suspended dosing as a precaution to ensure the continued safety of all patients in its clinical trials. In these trials, iSONEP is being tested as a treatment for wet AMD and a related complication, Pigmented Epithelial D...